• A Corrigendum to this article was published on 06 June 2017

This article has been updated


Binding of the gp120 envelope (Env) glycoprotein to the CD4 receptor is the first step in the HIV-1 infectious cycle. Although the CD4-binding site has been extensively characterized, the initial receptor interaction has been difficult to study because of major CD4-induced structural rearrangements. Here we used cryogenic electron microscopy (cryo-EM) to visualize the initial contact of CD4 with the HIV-1 Env trimer at 6.8-Å resolution. A single CD4 molecule is embraced by a quaternary HIV-1–Env surface formed by coalescence of the previously defined CD4-contact region with a second CD4-binding site (CD4-BS2) in the inner domain of a neighboring gp120 protomer. Disruption of CD4-BS2 destabilized CD4-trimer interaction and abrogated HIV-1 infectivity by preventing the acquisition of coreceptor-binding competence. A corresponding reduction in HIV-1 infectivity occurred after the mutation of CD4 residues that interact with CD4-BS2. Our results document the critical role of quaternary interactions in the initial HIV-Env-receptor contact, with implications for treatment and vaccine design.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 27 April 2017

    In the version of this article initially published, funding information for B.C. and C.S.P. was missing NIH grant S10 OD019994-01. In addition, there was an incorrect comma in the introduction (after "glycoprotein" in the sentence "Upon binding to the primary cellular receptor, CD4, the external gp120 Env glycoprotein undergoes major conformational changes...") that has been removed. The errors have been corrected in the HTML and PDF versions of the article.


Primary accessions

Electron Microscopy Data Bank

Protein Data Bank


  1. 1.

    & The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884–1888 (1998).

  2. 2.

    & HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254, 225–244 (2013).

  3. 3.

    et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678–682 (2002).

  4. 4.

    et al. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50, 975–985 (1987).

  5. 5.

    et al. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J. Virol. 64, 5701–5707 (1990).

  6. 6.

    , & Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J. Virol. 77, 5889–5901 (2003).

  7. 7.

    et al. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol. Cell 37, 656–667 (2010).

  8. 8.

    et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648–659 (1998).

  9. 9.

    et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 8, 1329–1339 (2000).

  10. 10.

    et al. Structure of a V3-containing HIV-1 gp120 core. Science 310, 1025–1028 (2005).

  11. 11.

    et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. USA 107, 1166–1171 (2010).

  12. 12.

    et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342, 1484–1490 (2013).

  13. 13.

    et al. Trimeric HIV-1-env structures define glycan shields from clades A, B, and G. Cell 165, 813–826 (2016).

  14. 14.

    et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).

  15. 15.

    et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477–1483 (2013).

  16. 16.

    et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat. Struct. Mol. Biol. 22, 522–531 (2015).

  17. 17.

    et al. Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity 43, 1053–1063 (2015).

  18. 18.

    et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514, 455–461 (2014).

  19. 19.

    , , & Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J. Virol. 85, 2741–2750 (2011).

  20. 20.

    , & Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351, 1043–1048 (2016).

  21. 21.

    , , , & Molecular architecture of native HIV-1 gp120 trimers. Nature 455, 109–113 (2008).

  22. 22.

    et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 346, 759–763 (2014).

  23. 23.

    et al. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc. Natl. Acad. Sci. USA 108, 11440–11445 (2011).

  24. 24.

    et al. Broadly neutralizing antibody 8ANC195 recognizes closed and open states of HIV-1 Env. Cell 162, 1379–1390 (2015).

  25. 25.

    et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466–470 (2011).

  26. 26.

    et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13, 1032–1034 (2007).

  27. 27.

    et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285–289 (2009).

  28. 28.

    et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515, 138–142 (2014).

  29. 29.

    , , & Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer. PLoS One 10, e0122111 (2015).

  30. 30.

    , , , & Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res. Hum. Retroviruses 18, 1207–1217 (2002).

  31. 31.

    et al. A highly conserved gp120 inner domain residue modulates Env conformation and trimer stability. J. Virol. 90, 8395–8409 (2016).

  32. 32.

    et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280, 1949–1953 (1998).

  33. 33.

    et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732–737 (2007).

  34. 34.

    et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811–817 (2010).

  35. 35.

    et al. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 161, 1280–1292 (2015).

  36. 36.

    et al. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J. Virol. 86, 11231–11241 (2012).

  37. 37.

    et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593–1602 (2011).

  38. 38.

    et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 340, 751–756 (2013).

  39. 39.

    et al. Distinct cellular receptor interactions in poliovirus and rhinoviruses. EMBO J. 19, 1207–1216 (2000).

  40. 40.

    , , , & A cellular receptor of human rhinovirus type 2, the very-low-density lipoprotein receptor, binds to two neighboring proteins of the viral capsid. J. Virol. 77, 8504–8511 (2003).

  41. 41.

    et al. Structural and functional analysis of integrin α2I domain interaction with echovirus 1. J. Biol. Chem. 279, 11632–11638 (2004).

  42. 42.

    et al. Cryo-EM structure of a CD4-bound open HIV-1 envelope trimer reveals structural rearrangements of the gp120 V1V2 loop. Proc. Natl. Acad. Sci. USA 113, E7151–E7158 (2016).

  43. 43.

    et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317, 1930–1934 (2007).

  44. 44.

    et al. Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes. Cell 163, 1702–1715 (2015).

  45. 45.

    et al. Automated molecular microscopy: the new Leginon system. J. Struct. Biol. 151, 41–60 (2005).

  46. 46.

    et al. Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. Nat. Methods 10, 584–590 (2013).

  47. 47.

    et al. Automation in single-particle electron microscopy: connecting the pieces. Methods Enzymol. 483, 291–338 (2010).

  48. 48.

    et al. Appion: an integrated, database-driven pipeline to facilitate EM image processing. J. Struct. Biol. 166, 95–102 (2009).

  49. 49.

    Gctf: real-time CTF determination and correction. J. Struct. Biol. 193, 1–12 (2016).

  50. 50.

    , , , & DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy. J. Struct. Biol. 166, 205–213 (2009).

  51. 51.

    et al. A clustering approach to multireference alignment of single-particle projections in electron microscopy. J. Struct. Biol. 171, 197–206 (2010).

  52. 52.

    Particle finding in electron micrographs using a fast local correlation algorithm. Ultramicroscopy 94, 225–236 (2003).

  53. 53.

    FindEM—a fast, efficient program for automatic selection of particles from electron micrographs. J. Struct. Biol. 145, 91–99 (2004).

  54. 54.

    RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519–530 (2012).

  55. 55.

    et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).

  56. 56.

    et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336–343 (2011).

  57. 57.

    & Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. D Biol. Crystallogr. 60, 2256–2268 (2004).

  58. 58.

    et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235–242 (2011).

  59. 59.

    & Extending the accuracy limits of prediction for side-chain conformations. J. Mol. Biol. 311, 421–430 (2001).

  60. 60.

    & Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 (2007).

  61. 61.

    , & ACEMD: accelerating biomolecular dynamics in the microsecond time scale. J. Chem. Theory Comput. 5, 1632–1639 (2009).

Download references


We thank J.P. Moore and A. Cupo (Weill Medical College of Cornell University, New York, New York, USA) for providing plasmids for expression of the BG505 SOSIP.664 trimer and furin; M. Farzan (Scripps Research Institute, Jupiter, Florida, USA) for providing the plasmid to express human CD4-immunoglobulin; D.R. Burton (Scripps Research Institute, La Jolla, California, USA, and Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA), M. Connors (Laboratory of Immunoregulation, NIAID, NIH, Bethesda, Maryland, USA), J.R. Mascola (Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA), and J.E. Robinson (Tulane University School of Medicine, New Orleans, Louisiana, USA) for anti-gp120 mAbs; E. Berger (Laboratory of Viral Diseases, NIAID, NIG, Bethesda, Maryland, USA) for the full-length CD4 gene and the gene encoding gp160 from BG505-T332N and BaL; D. Ichikawa and Y. Lin for help in performing selected experiments; J. Arthos, E.A. Berger, and R. Cimbro for helpful discussion; P. Gangopadhyay for help with MATLAB and Origin; and the AIDS Reagent Program for providing the reagents indicated in the Online Methods. The GPU-enabled frame-alignment program we used was generously provided by Y. Cheng and X. Li. The cryo-EM work was done at the National Resource for Automated Molecular Microscopy based at the Simons Electron Microscopy Center, which is supported by grants from the NIH (GM103310 and S10 OD019994-01) and the Simons Foundation (349247) to B.C. and C.S.P. This research was supported by the Intramural Programs of the Vaccine Research Center and of the Division of Intramural Research, NIAID, NIH.

Author information

Author notes

    • Qingbo Liu
    •  & Priyamvada Acharya

    These authors contributed equally to this work.


  1. Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.

    • Qingbo Liu
    • , Peng Zhang
    • , Christina Guzzo
    • , Jacky Lu
    • , Alice Kwon
    • , Deepali Gururani
    • , Huiyi Miao
    •  & Paolo Lusso
  2. Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.

    • Priyamvada Acharya
    • , Tatsiana Bylund
    • , Gwo-Yu Chuang
    • , Aliaksandr Druz
    • , Tongqing Zhou
    •  & Peter D Kwong
  3. National Resource for Automated Molecular Microscopy, Simons Electron Microscopy Center, New York Structural Biology Center, New York, New York, USA.

    • Priyamvada Acharya
    • , William J Rice
    • , Christoph Wigge
    • , Bridget Carragher
    •  & Clinton S Potter
  4. Bioinformatics and Computational Biosciences Branch, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.

    • Michael A Dolan


  1. Search for Qingbo Liu in:

  2. Search for Priyamvada Acharya in:

  3. Search for Michael A Dolan in:

  4. Search for Peng Zhang in:

  5. Search for Christina Guzzo in:

  6. Search for Jacky Lu in:

  7. Search for Alice Kwon in:

  8. Search for Deepali Gururani in:

  9. Search for Huiyi Miao in:

  10. Search for Tatsiana Bylund in:

  11. Search for Gwo-Yu Chuang in:

  12. Search for Aliaksandr Druz in:

  13. Search for Tongqing Zhou in:

  14. Search for William J Rice in:

  15. Search for Christoph Wigge in:

  16. Search for Bridget Carragher in:

  17. Search for Clinton S Potter in:

  18. Search for Peter D Kwong in:

  19. Search for Paolo Lusso in:


Q.L. and P.L. conceived the project and designed biological and virological studies; P.A., T.Z., and P.D.K. conceived and designed structural studies; Q.L., J.L., and D.G. mutagenized gp160 from different HIV-1 isolates and produced infectious pseudoparticles; Q.L., C.G., H.M., and A.K. carried out infectivity assays and antigenicity studies of surface-expressed Envs; Q.L., D.G., and P.Z. produced and purified mutants of SOSIP trimer and gp120 monomer; Q.L. characterized the purified proteins and performed immunogenicity studies and CD4-binding and CCR5-binding assays; A.D. expressed DS-SOSIP proteins for SPR and cryo-EM studies; Q.L. and P.A. purified CD4-BS2 mutants of DS-SOSIP trimer and performed SPR analysis of CD4 binding; P.A. purified DS-SOSIP, prepared the DS-SOSIP-CD4-PGT145 complex, and performed cryo-EM experiments, with W.J.R. and C.W. providing assistance with electron microscopy data collection; P.A., T.B., G.-Y.C., and T.Z. analyzed the structure; M.A.D. performed docking experiments and MD simulations; B.C., C.S.P., and P.D.K. supervised cryo-EM experiments and structural analyses; Q.L., P.A., P.D.K., and P.L. analyzed data and wrote the paper; and all coauthors read and commented on the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Paolo Lusso.

Integrated supplementary information

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–9 and Supplementary Tables 1–3

Excel files

  1. 1.

    Supplementary Table 4

    BSA for various trimers

About this article

Publication history






Further reading